GenMont Biotech Incorporation (TPE:3164)
Taiwan · Delayed Price · Currency is TWD 17.95
-0.05 (-0.28%)
Mar 24, 2026, 1:30 PM CST
TPE:3164 Revenue
In the year 2025, GenMont Biotech Incorporation had annual revenue of 401.23M TWD with 4.11% growth. GenMont Biotech Incorporation had revenue of 100.70M in the quarter ending December 31, 2025, with 10.72% growth.
Revenue
401.23M
Revenue Growth
+4.11%
P/S Ratio
3.85
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 401.23M | 15.86M | 4.11% |
| Dec 31, 2024 | 385.37M | 67.36M | 21.18% |
| Dec 31, 2023 | 318.02M | -50.53M | -13.71% |
| Dec 31, 2022 | 368.55M | -59.38M | -13.88% |
| Dec 31, 2021 | 427.93M | 102.74M | 31.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genomics BioSci & Tech. | 607.89M |
| Meribank Biotech | 486.52M |
| Abnova (Taiwan) | 351.30M |
| NeoCore Technology | 244.66M |
| Gwo Xi Stem Cell Applied Technology Co. , | 184.91M |
| Lukas Biomedical | 180.32M |
| Enimmune | 42.23M |
| TaiRx | 15.46M |